Company Filing History:
Years Active: 2015-2016
Title: Silvia Kaden-Vagt: Innovator in Insulin Therapeutics
Introduction
Silvia Kaden-Vagt is a prominent inventor based in Heidelberg, Germany. She has made significant contributions to the field of pharmaceuticals, particularly in the development of insulin-related therapies. With a total of 3 patents to her name, her work has the potential to impact the treatment of various diseases.
Latest Patents
One of her latest patents is focused on prodrugs comprising an insulin linker conjugate. This invention relates to a prodrug or a pharmaceutically acceptable salt that includes an insulin linker conjugate D-L. In this context, D represents the insulin moiety, while -L is a non-biologically active linker moiety. The invention also encompasses pharmaceutical compositions that utilize these prodrugs for treating or preventing diseases that can be managed with insulin. Another notable patent is for a long-acting insulin composition. This pharmaceutical composition is designed to maintain a therapeutically effective level of insulin in blood plasma for at least three days, characterized by a pharmacokinetic profile that avoids a burst of the insulin compound.
Career Highlights
Throughout her career, Silvia has worked with notable companies such as Sanofi-Aventis Deutschland GmbH and Ascendis Pharma A/S. Her experience in these organizations has allowed her to refine her expertise in pharmaceutical development and innovation.
Collaborations
Silvia has collaborated with esteemed colleagues, including Felix Cleemann and Ulrich Hersel. These partnerships have contributed to her success and the advancement of her research.
Conclusion
Silvia Kaden-Vagt is a trailblazer in the field of insulin therapeutics, with her innovative patents paving the way for improved treatment options. Her work exemplifies the impact of dedicated research and collaboration in the pharmaceutical industry.